Is Hims & Hers Really the Growth Stock to Buy That It Appears?

Hims Shares Set for Record Week as New Novo Pact Fuels Optimism

Hims & Hers Health Inc. shares are on pace for their best week on record as a new partnership with Novo Nordisk A/S fuels fresh optimism about the company’s future in weight-loss drugs.

Is Hims & Hers Really the Growth Stock to Buy That It Appears?

Quick Read Hims & Hers (HIMS) agreed to sell branded Wegovy and Ozempic directly on its platform while discontinuing most compounded GLP-1 advertising, resolving a patent lawsuit with Novo Nordisk and removing regulatory and legal risks that had cratered shares 75%. Novo Nordisk dropped its patent-infringement lawsuit against Hims and granted the telehealth platform distribution rights to its branded weight-loss drugs, including the new oral We…

Does This Deal Make Novo Nordisk Stock a Buy?

Key PointsNovo Nordisk will partner with Hims & Hers to sell affordable branded semaglutide. This will decrease competition from compounded versions of the drug.Beyond this deal, there are several reasons to buy Novo Nordisk stock. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) has faced several headwinds over the past two years. The company suffered clinical setbacks while losing market share to its biggest competitor, El…